Compare CAR & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAR | RYTM |
|---|---|---|
| Founded | 1946 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 6.4B |
| IPO Year | 1998 | 2017 |
| Metric | CAR | RYTM |
|---|---|---|
| Price | $148.35 | $76.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $127.57 | ★ $131.14 |
| AVG Volume (30 Days) | 629.1K | ★ 914.5K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.71 | 28.34 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,652,000,000.00 | N/A |
| Revenue This Year | $2.17 | $55.17 |
| Revenue Next Year | $1.78 | $95.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $62.17 | $45.91 |
| 52 Week High | $212.81 | $122.20 |
| Indicator | CAR | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 81.74 | 31.50 |
| Support Level | $147.93 | $60.71 |
| Resistance Level | $163.57 | $98.37 |
| Average True Range (ATR) | 8.29 | 5.71 |
| MACD | 5.91 | -0.74 |
| Stochastic Oscillator | 99.39 | 0.08 |
Avis Budget Group Inc is a provider of mobility solutions through its three brands Avis, Budget and Zipcar, as well as several other brands, well recognized in their respective markets. Its brands offer a range of options, from car and truck rental to car sharing. The company operates in two reportable business segments: Americas - (i) vehicle rental operations in North America, South America, Central America and the Caribbean, (ii) car sharing operations in certain of these markets, and (iii) licensees in the areas in which do not operate directly. International - consisting of (i) vehicle rental operations in Europe, the Middle East, Africa, Asia and Australasia, (ii) car sharing operations in certain of these markets, and (iii) licensees in the areas in which do not operate directly.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.